Loading clinical trials...
Loading clinical trials...
Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study
Conditions
Interventions
ALLN-177
Placebo
Locations
63
United States
Urology Centers of Alabama
Birmingham, Alabama, United States
University of Alabama, Department of Urology
Birmingham, Alabama, United States
Mayo Clinic Hospital
Phoenix, Arizona, United States
Urological Associates of Southern Arizona
Tucson, Arizona, United States
Applied Research Center of Arkansas
Little Rock, Arkansas, United States
TROVARE Clinical Research
Bakersfield, California, United States
Start Date
May 21, 2018
Primary Completion Date
September 30, 2019
Completion Date
October 28, 2019
Last Updated
February 27, 2020
NCT04629170
NCT05650112
Lead Sponsor
Allena Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions